CND Life Sciences completes its Series Seed 3 round, raising a total of $12.5 million in equity
CND Life Sciences, a medical technology company that has pioneered the development of reliable skin-based tests to assist clinicians in diagnosing neurodegenerative disorders such as Parkinson’s disease and dementia with Lewy bodies, announced today the completion of a $4.5 million Series Seed 3 equity financing round. This additional funding brings the Company’s total Seed funding … Read more